GAO evaluation of device reuse
This article was originally published in The Gray Sheet
Executive Summary
Senate Health, Education, Labor and Pensions Committee in July 26 letter to the General Accounting Office asks the investigative body to evaluate the appropriateness of FDA's current reprocessing policy, which "does not distinguish between different classes and types of medical devices (i.e., can some single-use devices be safely reprocessed but not others)." The committee members also ask GAO to analyze additional questions regarding reprocessing, such as the economic impact of reusing disposable products and the cost of requiring FDA to assure the safety and efficacy of reprocessed single-use devices for their intended use (1"The Gray Sheet" July 26, p. 7)
You may also be interested in...
GAO Inquiry Into Device Reprocessing, FDA Oversight To Be Sought By Senate
The Senate Health, Education, Labor and Pensions Committee will ask the General Accounting Office to undertake a comprehensive evaluation of the practice of reprocessing devices, according to committee staffers.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.